Globes [online] is reporting that a company called Nicast is starting European trials of its peripheral vascular grafts. The firm’s devices are made of Endoluminal Matrix Morphology technology, a proprietary poly-urethane nanometric scale fiber scaffolding that is thought to promote endothelialization of the grafts and, more importantly, allow grafts to self-seal following a needle puncture. In the picture, the Nicast graft is on the left and the ePTFE graft is on the right, both following 16G needle puncture.
To learn more about Nicast technology…